Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zheng, Mei ^a   Qu, Di ^b   Wang, Haiming ^a   Sun, Zhiping ^b   Liu, Xueying ^a   Chen, Jianjun ^c   Li, Changgui ^d   Li, Xuguang ^e   Chen, Ze ^a,f  

^a SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^b FUDAN UNIVERSITY   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^e HEALTH CANADA   (Canada)

^f HUNAN NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN;

ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; IMMUNOLOGY; INFLUENZA A VIRUS (H7N9); INNATE IMMUNITY; INTRANASAL DRUG ADMINISTRATION; MOUSE; ORTHOMYXOVIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; CHITOSAN; IMMUNITY, INNATE; INFLUENZA A VIRUS, H7N9 SUBTYPE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84976622073     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28729     Document Type: Article

References (50)

1. Carrat, F. & Flahault, A. Influenza vaccine: The challenge of antigenic drift. Vaccine 25, 6852-6862 (2007).
2. Dortmans, J. C. et al. Adaptation of novel H7N9 influenza A virus to human receptors. Sci Rep 3, 3058 (2013).
3. WHO. Human infection with avian influenza A(H7N9) virus-update. http://www.who.int/csr/don/2013-08-11/en/(2013) (Date of access: 11/08/2013).
4. Qi, X. et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ 347, f4752 (2013).
5. Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Me 368, 1888-1897 (2013).
6. General Administration of Quality Supervision, Inspection and Quarantine of the Peoples Republic of China. One more human H7N9 case in China. http://www.aqsiq.gov.cn/xxgk-13386/tsxx/yqts/201506/t20150615-442593.htm (2015) (Date of access: 15/06/2015).
7. General Administration of Quality Supervision, Inspection and Quarantine of the Peoples Republic of China.One more human H7N9 case in China. http://www.aqsiq.gov.cn/xxgk13386/tsxx/yqts/201511/t20151106-453363.htm (2015) (Date of access: 06/11/2015).
8. General Administration of Quality Supervision, Inspection and Quarantine of the Peoples Republic of China. One more human H7N9 case in China. http://www.aqsiq.gov.cn/xxgk-13386/tsxx/yqts/201512/t20151204-455629.htm (2015) (Date of access: 04/12/2015).
9. Hu, Y. et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381, 2273-2279 (2013).
10. Ludwig, S., Planz, O., Pleschka, S. & Wolff, T. Influenza-virus-induced signaling cascades: Targets for antiviral therapy? Trends Mol Med 9, 46-52 (2003).
11. Palese, P. Influenza: old and new threats. Nat Med 10, S82-S87 (2004).
12. Brown, E. G. Influenza virus genetics. Biomed Pharmacother 54, 196-209 (2000).
13. de Jong, M. D. et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353, 2667-2672 (2005).
14. Yen, H. L. et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio 4, e00396-13 (2013).
15. Huber, V. C. et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13, 981-990 (2006).
16. Topham, D. J., Tripp, R. A. & Doherty, P. C. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159, 5197-5200 (1997).
17. Arnon, T. I., Markel, G. & Mandelboim, O. Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol 16, 348-358 (2006).
18. Dokun, A. O., Chu, D. T., Yang, L., Bendelac, A. S. & Yokoyama, W. M. Analysis of in situ NK cell responses during viral infection. J Immunol 167, 5286-5293 (2001).
19. Dokun, A. O. et al. Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2, 951-956 (2001).
20. Tay, C. H., Szomolanyi-Tsuda, E. & Welsh, R. M. Control of infections by NK cells, Curr Top Microbiol Immunol 230, 193-220 (1998).
21. Norton, E. B., Clements, J. D., Voss, T. G. & Cárdenas-Freytag, L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol 84, 2983-2895 (2010).
22. Sui, Z., Chen, Q., Fang, F., Zheng, M. & Chen, Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28, 7690-7698 (2010).
23. Sui, Z. et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol 155, 5535-5544 (2010).
24. Hannoun, C., Megas, F. & Piercy, J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103, 133-138 (2004).
25. Gerhard, W., Mozdzanowska, K. & Zharikova, D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 12, 569-574 (2006).
26. Drape, R. J. et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24, 4475-4481 (2006).
27. Fedson, D. S. Pandemic influenza and the global vaccine supply. Clin Infect Dis 36, 1552-1561 (2003).
28. Centers for Disease Control and Prevention (CDC). Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine-Colorado, December 2003. MMWR Morb Mortal Wkly Rep 53, 8-11 (2004).
29. Nordin, J. et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 184, 665-670 (2001).
30. Puthavathana, P. et al. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol 86, 423-433 (2005).
31. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, et al. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med 360, 2605-2615 (2009).
32. Demedts, I. K., Bracke, K. R., Maes, T., Joos, G. F. & Brusselle, G. G. Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am J Respir Cell Mol Biol 35, 387-393 (2006).
33. Piet, B. et al. CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest 121, 2254-2263 (2011).
34. Beilharz, M. W., Cummins, J. M. & Bennett, A. L. Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem Biophys Res Commun 355, 740-744 (2007).
35. Lau, Y. F., Tang, L. H. & Ooi, E. E. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27, 1354-1364 (2009).
36. Debono, M. & Gordee, R. S. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 48, 471-497 (1994).
37. Georgopapadakou, N. H. & Tkacz, J. S. The fungal cell wall as a drug target. Trends Microbiol 3, 98-104 (1995).
38. Kim, T. J., Kim. K. H. & Lee. J. I. Stimulation of mucosal and systemic antibody responses against recombinant transferrin-binding protein B of Actinobacillus pleuropneumoniae with chitosan after tracheal administration in piglets. The Journal of veterinary medical science 69, 535-539 (2007).
39. Reese, T. A. et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 447, 92-96 (2007).
40. Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178, 2243-2247 (1993).
41. Azuma, I. Synthetic immunoadjuvants: Application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 10, 1000-1006 (1992).
42. Rollins, B. J. Chemokines. Blood 90, 909-928 (1997).
43. Hashimoto, Y., Moki, T., Takizawa, T., Shiratsuchi, A. & Nakanishi, Y. Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol 178, 2448-2457 (2007).
44. Tate, M. D. et al. The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One 6, e17618 (2011).
45. Tate, M. D., Brooks, A. & Reading, P. C. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir Res 9, 57 (2008).
46. Qiu, M. et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin-or neuraminidaseexpressing DNA in BALB/c mice. Biochem Biophys Res Commun 343, 1124-1131 (2006).
47. Zhang, F. et al. Maternal immunization with both hemagglutinin-And neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell Biol 24, 758-765 (2005).
48. Zhu, Q. et al. Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice. Biochem Biophys Res Commun 329, 87-89 (2005).
49. Guo, L. et al. Protection against multiple influenza A subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol 155, 1765-1775 (2010).
50. Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493-497 (1938).